摘要
目的探讨血清血管内皮生长因子(VEGF)、细胞角蛋白片段19抗原21-1(CYFRA21-1)水平变化与浸润性膀胱癌患者临床分期的关联性。方法选取我院2016年11月-2018年9月83例不同临床分期浸润性膀胱癌患者设为恶性组,另选取同期收治的83例膀胱良性肿瘤疾病患者设为良性组、83例健康体检者设为健康组。入院后第2 d晨起时抽取各组空腹静脉血4 ml,以化学发光免疫法测定血清CYFRA21-1水平,以酶联免疫吸附法测定血清VEGF水平。统计分析三组血清CYFRA21-1、VEGF水平及恶性组不同远处转移情况患者、不同分化程度患者、不同临床分期浸润性膀胱癌患者血清CYFR A21-1及VEGF水平,并统计分析血清CYFRA21-1及VEGF水平与浸润性膀胱癌临床分期间相关性。结果单因素方差检验可知,三组血清CYFRA21-1及VEGF水平间存在显著差异(P<0.05),多重比较,良性组血清CYFRA21-1及VEGF水平高于健康组(P<0.05),恶性组血清CYFRA21-1及VEGF水平高于良性组(P<0.05);发生远处转移的浸润性膀胱癌患者血清CYFRA21-1及VEGF水平高于未发生远处转移的浸润性膀胱癌患者(P<0.05);低分化浸润性膀胱癌患者血清CYFRA21-1及VEGF水平高于高中分化浸润性膀胱癌患者(P<0.05);不同临床分期浸润性膀胱癌患者血清CYFRA21-1及VEGF水平间存在显著差异(P<0.05),多重比较,Ⅳ期浸润性膀胱癌患者血清CYFRA21-1及VEGF水平高于Ⅲ期患者(P<0.05),Ⅲ期浸润性膀胱癌患者血清CYFRA21-1及VEGF水平高于Ⅰ+Ⅱ期者(P<0.05);Pearson检验可知,血清CYFRA21-1及VEGF水平与浸润性膀胱癌临床分期间存在显著正相关关系(P<0.05)。结论浸润性膀胱癌患者VEGF及CYFRA21-1血清含量显著增高,于发生远处转移及低分化者中增高幅度更加显著,且其表达水平随浸润性膀胱癌临床分期增高而增高,两者间存在显著正相关关系。
Objective To investigate the relationship between serum vascular endothelial growth factor(VEGF), cytokeratin fragment 19-1(CYFRA21-1) levels and clinical stage of patients with invasive bladder cancer. Methods From November 2016 to September 2018, 83 patients with invasive bladder cancer were enrolled in the malignant group. Eighty-three patients with benign bladder disease were enrolled in the benign group and 83 healthy subjects were set as healthy group. On the 2 nd day after admission, 4 ml of fasting venous blood was taken from each individual. Serum CYFRA21-1 level was determined by chemiluminescence immunoassay, and serum VEGF level was determined by enzyme-linked immunosorbent assay. Statistically analyze serum CYFRA21-1, VEGF levels in patients with different levels of CYFRA21-1, VEGF, and patients with different distant metastasis,patients with different degrees of differentiation, and patients with different clinical stages of invasive bladder cancer, and statistical analysis of serum CYFRA21-1 and correlation between VEGF levels and clinical stage of invasive bladder cancer. Results One-way variance test showed that there were significant differences between the three groups of serum CYFRA21-1 and VEGF levels(P<0.05). The multiple comparisons showed that the serum levels of CYFRA21-1 and VEGF in the benign group were higher than those in the healthy group(P<0.05). The serum levels of CYFRA21-1 and VEGF were higher than those in the benign group(P<0.05). The levels of serum CYFRA21-1 and VEGF in patients with invasive bladder cancer with distant metastasis were higher than those in patients with invasive bladder cancer without distant metastasis(P<0.05);serum CYFRA21-1 and VEGF levels in patients with poorly differentiated invasive bladder cancer were higher than those in high-invasive bladder cancer(P<0.05);there was significant differences between serum CYFRA21-1 and VEGF levels in patients with different clinical stage invasive bladder cancer.(P<0.05), multiple comparisons, serum levels of CYFRA21-1 and VEGF in patients with stage IV invasive bladder cancer were higher than those in stage III(P<0.05). Patients with stage III invasive bladder cancer had high serum CYFRA21-1 and VEGF levels. In the stage I+II(P<0.05);Pearson test showed that there was a significant positive correlation between serum CYFRA21-1 and VEGF levels and clinical stage of invasive bladder cancer(P<0.05). Conclusion The serum levels of VEGF and CYFRA21-1 in patients with invasive bladder cancer are significantly increased, and the increase is more significant in patients with distant metastasis and poor differentiation, and the expression level increases with the clinical stage of invasive bladder cancer. Significant positive correlation.
作者
王利霞
WANG Lixia(Laboratory Anyang People's Hospital of Henan Anyang,455000)
出处
《实验与检验医学》
CAS
2020年第2期234-237,240,共5页
Experimental and Laboratory Medicine
